{"transactions":[{"id":730415,"issuer":{"id":4569,"kind":"organization","name":"Kardigan, Inc."},"owners":[{"id":36315,"kind":"person","name":"GIANAKAKOS ANASTASIOS","position":1,"cik":"0001413822","reported_name":"GIANAKAKOS ANASTASIOS","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Series B Preferred Stock","published_at":"2026-06-22T23:17:30.000Z","date":"2026-06-17","kind":"exercise","planned":false,"acquired":false,"shares":313092,"ownership":{"direct":false,"nature":"By spouse"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Preferred Stock and Series B Preferred Stock (together the \"Preferred Stock\") was convertible into Common Stock on a 1.5928 for 1 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 upon the effectiveness of the Issuer's registration statement on Form S-1 relating to its initial public offering on June 17, 2026 and without payment of consideration. The Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Preferred Stock and Series B Preferred Stock (together the \"Preferred Stock\") was convertible into Common Stock on a 1.5928 for 1 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 upon the effectiveness of the Issuer's registration statement on Form S-1 relating to its initial public offering on June 17, 2026 and without payment of consideration. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Preferred Stock and Series B Preferred Stock (together the \"Preferred Stock\") was convertible into Common Stock on a 1.5928 for 1 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 upon the effectiveness of the Issuer's registration statement on Form S-1 relating to its initial public offering on June 17, 2026 and without payment of consideration. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Preferred Stock and Series B Preferred Stock (together the \"Preferred Stock\") was convertible into Common Stock on a 1.5928 for 1 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 upon the effectiveness of the Issuer's registration statement on Form S-1 relating to its initial public offering on June 17, 2026 and without payment of consideration. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 of the Exchange Act, except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that he is a beneficial owner of such shares for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":498692},"source":{"system":"sec-edgar","filing":"0001193125-26-277916","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1413822/000119312526277916/ownership.xml","form_type":"4"}},{"id":730414,"issuer":{"id":4569,"kind":"organization","name":"Kardigan, Inc."},"owners":[{"id":36315,"kind":"person","name":"GIANAKAKOS ANASTASIOS","position":1,"cik":"0001413822","reported_name":"GIANAKAKOS ANASTASIOS","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Series A Preferred Stock","published_at":"2026-06-22T23:17:30.000Z","date":"2026-06-17","kind":"exercise","planned":false,"acquired":false,"shares":25742,"ownership":{"direct":false,"nature":"By KCM 2023 Trust"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Preferred Stock and Series B Preferred Stock (together the \"Preferred Stock\") was convertible into Common Stock on a 1.5928 for 1 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 upon the effectiveness of the Issuer's registration statement on Form S-1 relating to its initial public offering on June 17, 2026 and without payment of consideration. The Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Preferred Stock and Series B Preferred Stock (together the \"Preferred Stock\") was convertible into Common Stock on a 1.5928 for 1 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 upon the effectiveness of the Issuer's registration statement on Form S-1 relating to its initial public offering on June 17, 2026 and without payment of consideration. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Preferred Stock and Series B Preferred Stock (together the \"Preferred Stock\") was convertible into Common Stock on a 1.5928 for 1 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 upon the effectiveness of the Issuer's registration statement on Form S-1 relating to its initial public offering on June 17, 2026 and without payment of consideration. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Preferred Stock and Series B Preferred Stock (together the \"Preferred Stock\") was convertible into Common Stock on a 1.5928 for 1 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 upon the effectiveness of the Issuer's registration statement on Form S-1 relating to its initial public offering on June 17, 2026 and without payment of consideration. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Represents shares held by KCM 2023 Trust. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 of the Exchange Act, except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that he is a beneficial owner of such shares for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":41001},"source":{"system":"sec-edgar","filing":"0001193125-26-277916","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1413822/000119312526277916/ownership.xml","form_type":"4"}},{"id":730413,"issuer":{"id":4569,"kind":"organization","name":"Kardigan, Inc."},"owners":[{"id":36315,"kind":"person","name":"GIANAKAKOS ANASTASIOS","position":1,"cik":"0001413822","reported_name":"GIANAKAKOS ANASTASIOS","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Series A Preferred Stock","published_at":"2026-06-22T23:17:30.000Z","date":"2026-06-17","kind":"exercise","planned":false,"acquired":false,"shares":18020,"ownership":{"direct":false,"nature":"By AEG 2021 Trust"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Preferred Stock and Series B Preferred Stock (together the \"Preferred Stock\") was convertible into Common Stock on a 1.5928 for 1 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 upon the effectiveness of the Issuer's registration statement on Form S-1 relating to its initial public offering on June 17, 2026 and without payment of consideration. The Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Preferred Stock and Series B Preferred Stock (together the \"Preferred Stock\") was convertible into Common Stock on a 1.5928 for 1 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 upon the effectiveness of the Issuer's registration statement on Form S-1 relating to its initial public offering on June 17, 2026 and without payment of consideration. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Preferred Stock and Series B Preferred Stock (together the \"Preferred Stock\") was convertible into Common Stock on a 1.5928 for 1 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 upon the effectiveness of the Issuer's registration statement on Form S-1 relating to its initial public offering on June 17, 2026 and without payment of consideration. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Preferred Stock and Series B Preferred Stock (together the \"Preferred Stock\") was convertible into Common Stock on a 1.5928 for 1 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 upon the effectiveness of the Issuer's registration statement on Form S-1 relating to its initial public offering on June 17, 2026 and without payment of consideration. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Represents shares held by AEG 2021 Trust. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that he is a beneficial owner of such shares for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":28702},"source":{"system":"sec-edgar","filing":"0001193125-26-277916","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1413822/000119312526277916/ownership.xml","form_type":"4"}},{"id":730412,"issuer":{"id":4569,"kind":"organization","name":"Kardigan, Inc."},"owners":[{"id":36315,"kind":"person","name":"GIANAKAKOS ANASTASIOS","position":1,"cik":"0001413822","reported_name":"GIANAKAKOS ANASTASIOS","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2026-06-22T23:17:30.000Z","date":"2026-06-17","kind":"exercise","planned":false,"acquired":true,"shares":498692,"ownership":{"direct":false,"nature":"By spouse"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Preferred Stock and Series B Preferred Stock (together the \"Preferred Stock\") was convertible into Common Stock on a 1.5928 for 1 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 upon the effectiveness of the Issuer's registration statement on Form S-1 relating to its initial public offering on June 17, 2026 and without payment of consideration. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 of the Exchange Act, except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that he is a beneficial owner of such shares for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":498692,"source":{"system":"sec-edgar","filing":"0001193125-26-277916","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1413822/000119312526277916/ownership.xml","form_type":"4"}},{"id":730411,"issuer":{"id":4569,"kind":"organization","name":"Kardigan, Inc."},"owners":[{"id":36315,"kind":"person","name":"GIANAKAKOS ANASTASIOS","position":1,"cik":"0001413822","reported_name":"GIANAKAKOS ANASTASIOS","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2026-06-22T23:17:30.000Z","date":"2026-06-17","kind":"exercise","planned":false,"acquired":true,"shares":41001,"ownership":{"direct":false,"nature":"By KCM 2023 Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Preferred Stock and Series B Preferred Stock (together the \"Preferred Stock\") was convertible into Common Stock on a 1.5928 for 1 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 upon the effectiveness of the Issuer's registration statement on Form S-1 relating to its initial public offering on June 17, 2026 and without payment of consideration. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Represents shares held by KCM 2023 Trust. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 of the Exchange Act, except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that he is a beneficial owner of such shares for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":2422520,"source":{"system":"sec-edgar","filing":"0001193125-26-277916","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1413822/000119312526277916/ownership.xml","form_type":"4"}},{"id":730410,"issuer":{"id":4569,"kind":"organization","name":"Kardigan, Inc."},"owners":[{"id":36315,"kind":"person","name":"GIANAKAKOS ANASTASIOS","position":1,"cik":"0001413822","reported_name":"GIANAKAKOS ANASTASIOS","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2026-06-22T23:17:30.000Z","date":"2026-06-17","kind":"exercise","planned":false,"acquired":true,"shares":28702,"ownership":{"direct":false,"nature":"By AEG 2021 Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Preferred Stock and Series B Preferred Stock (together the \"Preferred Stock\") was convertible into Common Stock on a 1.5928 for 1 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 upon the effectiveness of the Issuer's registration statement on Form S-1 relating to its initial public offering on June 17, 2026 and without payment of consideration. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Represents shares held by AEG 2021 Trust. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that he is a beneficial owner of such shares for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":5665090,"source":{"system":"sec-edgar","filing":"0001193125-26-277916","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1413822/000119312526277916/ownership.xml","form_type":"4"}},{"id":1634116,"issuer":{"id":9881,"kind":"organization","name":"LianBio"},"owners":[{"id":36315,"kind":"person","name":"GIANAKAKOS ANASTASIOS","position":1,"cik":"0001413822","reported_name":"GIANAKAKOS ANASTASIOS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-02-20T21:11:33.000Z","date":"2024-02-15","kind":"exercise","planned":false,"acquired":false,"shares":36300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the option became exercisable in full on June 23, 2023."}],"balance_after":0,"derivative":{"exercise_price":2.52,"expiration_date":"2032-06-23","underlying":"Ordinary Shares","underlying_shares":36300},"source":{"system":"sec-edgar","filing":"0001831283-24-000011","document":"wk-form4_1708463476.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1831283/000183128324000011/wk-form4_1708463476.xml","form_type":"4"}},{"id":1634115,"issuer":{"id":9881,"kind":"organization","name":"LianBio"},"owners":[{"id":36315,"kind":"person","name":"GIANAKAKOS ANASTASIOS","position":1,"cik":"0001413822","reported_name":"GIANAKAKOS ANASTASIOS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2024-02-20T21:11:33.000Z","date":"2024-02-15","kind":"tax_withholding","planned":false,"acquired":false,"shares":19218,"price":4.76,"value":91477.68,"ownership":{"direct":true},"balance_after":53630,"source":{"system":"sec-edgar","filing":"0001831283-24-000011","document":"wk-form4_1708463476.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1831283/000183128324000011/wk-form4_1708463476.xml","form_type":"4"}},{"id":1634114,"issuer":{"id":9881,"kind":"organization","name":"LianBio"},"owners":[{"id":36315,"kind":"person","name":"GIANAKAKOS ANASTASIOS","position":1,"cik":"0001413822","reported_name":"GIANAKAKOS ANASTASIOS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2024-02-20T21:11:33.000Z","date":"2024-02-15","kind":"exercise","planned":false,"acquired":true,"shares":36300,"price":2.52,"value":91476.0,"ownership":{"direct":true},"balance_after":72848,"source":{"system":"sec-edgar","filing":"0001831283-24-000011","document":"wk-form4_1708463476.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1831283/000183128324000011/wk-form4_1708463476.xml","form_type":"4"}},{"id":1845386,"issuer":{"id":9881,"kind":"organization","name":"LianBio"},"owners":[{"id":36315,"kind":"person","name":"GIANAKAKOS ANASTASIOS","position":1,"cik":"0001413822","reported_name":"GIANAKAKOS ANASTASIOS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-23T20:22:08.000Z","date":"2023-06-21","kind":"grant","planned":false,"acquired":true,"shares":36300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the option shall vest and become exercisable in full on June 21, 2024, the first anniversary of the grant date, subject to the Reporting Person providing continuous service to the Issuer through such date."}],"balance_after":36300,"derivative":{"exercise_price":2.4,"expiration_date":"2033-06-21","underlying":"Ordinary Shares","underlying_shares":36300},"source":{"system":"sec-edgar","filing":"0001831283-23-000094","document":"wk-form4_1687551713.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1831283/000183128323000094/wk-form4_1687551713.xml","form_type":"4"}},{"id":2221316,"issuer":{"id":9881,"kind":"organization","name":"LianBio"},"owners":[{"id":36315,"kind":"person","name":"GIANAKAKOS ANASTASIOS","position":1,"cik":"0001413822","reported_name":"GIANAKAKOS ANASTASIOS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2022-06-27T20:17:56.000Z","date":"2022-06-23","kind":"grant","acquired":true,"shares":36300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the option shall vest and become exercisable in full on June 23, 2023, the first anniversary of the grant date, subject to the Reporting Person providing continuous service to the Issuer through such date."}],"balance_after":36300,"derivative":{"exercise_price":2.52,"expiration_date":"2032-06-23","underlying":"Ordinary Shares","underlying_shares":36300},"source":{"system":"sec-edgar","filing":"0001831283-22-000050","document":"wf-form4_165636106038470.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1831283/000183128322000050/wf-form4_165636106038470.xml","form_type":"4"}},{"id":2454540,"issuer":{"id":9881,"kind":"organization","name":"LianBio"},"owners":[{"id":36315,"kind":"person","name":"GIANAKAKOS ANASTASIOS","position":1,"cik":"0001413822","reported_name":"GIANAKAKOS ANASTASIOS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-01-03T21:20:13.000Z","date":"2021-12-29","kind":"exercise","acquired":false,"shares":36548,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares underlying the option vested and became exercisable on the first anniversary of the commencement date, December 17, 2021; the remainder shall vest and become exercisable in 3 equal annual installments such that the option shall be fully vested on December 17, 2024, subject to the Reporting Person providing continuous service to the Issuer on each such date."}],"balance_after":109647,"derivative":{"exercise_price":6.49,"expiration_date":"2030-12-17","underlying":"Ordinary Shares","underlying_shares":36548},"source":{"system":"sec-edgar","filing":"0000899243-22-000135","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1831283/000089924322000135/doc4.xml","form_type":"4"}},{"id":2454539,"issuer":{"id":9881,"kind":"organization","name":"LianBio"},"owners":[{"id":36315,"kind":"person","name":"GIANAKAKOS ANASTASIOS","position":1,"cik":"0001413822","reported_name":"GIANAKAKOS ANASTASIOS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2022-01-03T21:20:13.000Z","date":"2021-12-29","kind":"exercise","acquired":true,"shares":36548,"price":6.49,"value":237196.52,"ownership":{"direct":true},"balance_after":36548,"source":{"system":"sec-edgar","filing":"0000899243-22-000135","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1831283/000089924322000135/doc4.xml","form_type":"4"}},{"id":2972973,"issuer":{"id":145206,"kind":"organization","name":"MyoKardia, Inc.","symbol":"MYOK"},"owners":[{"id":36315,"kind":"person","name":"GIANAKAKOS ANASTASIOS","position":1,"cik":"0001413822","reported_name":"GIANAKAKOS ANASTASIOS","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to buy)","published_at":"2020-11-20T01:15:34.000Z","date":"2020-11-17","kind":"disposition_to_issuer","acquired":false,"shares":142733,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option."}],"balance_after":0,"derivative":{"exercise_price":70.4,"underlying":"Common Stock","underlying_shares":142733},"source":{"system":"sec-edgar","filing":"0000899243-20-031746","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1413822/000089924320031746/doc4.xml","form_type":"4"}},{"id":2972972,"issuer":{"id":145206,"kind":"organization","name":"MyoKardia, Inc.","symbol":"MYOK"},"owners":[{"id":36315,"kind":"person","name":"GIANAKAKOS ANASTASIOS","position":1,"cik":"0001413822","reported_name":"GIANAKAKOS ANASTASIOS","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to buy)","published_at":"2020-11-20T01:15:34.000Z","date":"2020-11-17","kind":"disposition_to_issuer","acquired":false,"shares":236500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option."}],"balance_after":0,"derivative":{"exercise_price":40.11,"underlying":"Common Stock","underlying_shares":236500},"source":{"system":"sec-edgar","filing":"0000899243-20-031746","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1413822/000089924320031746/doc4.xml","form_type":"4"}},{"id":2972971,"issuer":{"id":145206,"kind":"organization","name":"MyoKardia, Inc.","symbol":"MYOK"},"owners":[{"id":36315,"kind":"person","name":"GIANAKAKOS ANASTASIOS","position":1,"cik":"0001413822","reported_name":"GIANAKAKOS ANASTASIOS","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to buy)","published_at":"2020-11-20T01:15:34.000Z","date":"2020-11-17","kind":"disposition_to_issuer","acquired":false,"shares":184100,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option."}],"balance_after":0,"derivative":{"exercise_price":52,"underlying":"Common Stock","underlying_shares":184100},"source":{"system":"sec-edgar","filing":"0000899243-20-031746","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1413822/000089924320031746/doc4.xml","form_type":"4"}},{"id":2972970,"issuer":{"id":145206,"kind":"organization","name":"MyoKardia, Inc.","symbol":"MYOK"},"owners":[{"id":36315,"kind":"person","name":"GIANAKAKOS ANASTASIOS","position":1,"cik":"0001413822","reported_name":"GIANAKAKOS ANASTASIOS","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to buy)","published_at":"2020-11-20T01:15:34.000Z","date":"2020-11-17","kind":"disposition_to_issuer","acquired":false,"shares":303500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option."}],"balance_after":0,"derivative":{"exercise_price":12.25,"underlying":"Common Stock","underlying_shares":303500},"source":{"system":"sec-edgar","filing":"0000899243-20-031746","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1413822/000089924320031746/doc4.xml","form_type":"4"}},{"id":2972969,"issuer":{"id":145206,"kind":"organization","name":"MyoKardia, Inc.","symbol":"MYOK"},"owners":[{"id":36315,"kind":"person","name":"GIANAKAKOS ANASTASIOS","position":1,"cik":"0001413822","reported_name":"GIANAKAKOS ANASTASIOS","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to buy)","published_at":"2020-11-20T01:15:34.000Z","date":"2020-11-17","kind":"disposition_to_issuer","acquired":false,"shares":72562,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option."}],"balance_after":0,"derivative":{"exercise_price":9.08,"underlying":"Common Stock","underlying_shares":72562},"source":{"system":"sec-edgar","filing":"0000899243-20-031746","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1413822/000089924320031746/doc4.xml","form_type":"4"}},{"id":2972968,"issuer":{"id":145206,"kind":"organization","name":"MyoKardia, Inc.","symbol":"MYOK"},"owners":[{"id":36315,"kind":"person","name":"GIANAKAKOS ANASTASIOS","position":1,"cik":"0001413822","reported_name":"GIANAKAKOS ANASTASIOS","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to buy)","published_at":"2020-11-20T01:15:34.000Z","date":"2020-11-17","kind":"disposition_to_issuer","acquired":false,"shares":149517,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option."}],"balance_after":0,"derivative":{"exercise_price":1.5068,"underlying":"Common Stock","underlying_shares":149517},"source":{"system":"sec-edgar","filing":"0000899243-20-031746","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1413822/000089924320031746/doc4.xml","form_type":"4"}},{"id":2972967,"issuer":{"id":145206,"kind":"organization","name":"MyoKardia, Inc.","symbol":"MYOK"},"owners":[{"id":36315,"kind":"person","name":"GIANAKAKOS ANASTASIOS","position":1,"cik":"0001413822","reported_name":"GIANAKAKOS ANASTASIOS","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2020-11-20T01:15:34.000Z","date":"2020-11-17","kind":"other","acquired":false,"shares":53087,"ownership":{"direct":false,"nature":"By Trust 3"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of October 3, 2020, by and among the Issuer, Bristol-Myers Squibb Company (\"Parent\"), and Gotham Merger Sub Inc., a direct wholly owned subsidiary of Parent (\"Merger Sub\"), pursuant to which Merger Sub completed a tender offer for shares of common stock of the Issuer (each, a \"Share\") and thereafter merged with and into the Issuer (the \"Merger\") effective as of November 17, 2020 (the \"Effective Time\"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $225.00 in cash (the \"Offer Price\") without interest and subject to applicable withholding taxes."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of October 3, 2020, by and among the Issuer, Bristol-Myers Squibb Company (\"Parent\"), and Gotham Merger Sub Inc., a direct wholly owned subsidiary of Parent (\"Merger Sub\"), pursuant to which Merger Sub completed a tender offer for shares of common stock of the Issuer (each, a \"Share\") and thereafter merged with and into the Issuer (the \"Merger\") effective as of November 17, 2020 (the \"Effective Time\"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $225.00 in cash (the \"Offer Price\") without interest and subject to applicable withholding taxes."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-20-031746","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1413822/000089924320031746/doc4.xml","form_type":"4"}},{"id":2972966,"issuer":{"id":145206,"kind":"organization","name":"MyoKardia, Inc.","symbol":"MYOK"},"owners":[{"id":36315,"kind":"person","name":"GIANAKAKOS ANASTASIOS","position":1,"cik":"0001413822","reported_name":"GIANAKAKOS ANASTASIOS","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2020-11-20T01:15:34.000Z","date":"2020-11-17","kind":"other","acquired":false,"shares":53087,"ownership":{"direct":false,"nature":"By Trust 2"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of October 3, 2020, by and among the Issuer, Bristol-Myers Squibb Company (\"Parent\"), and Gotham Merger Sub Inc., a direct wholly owned subsidiary of Parent (\"Merger Sub\"), pursuant to which Merger Sub completed a tender offer for shares of common stock of the Issuer (each, a \"Share\") and thereafter merged with and into the Issuer (the \"Merger\") effective as of November 17, 2020 (the \"Effective Time\"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $225.00 in cash (the \"Offer Price\") without interest and subject to applicable withholding taxes."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of October 3, 2020, by and among the Issuer, Bristol-Myers Squibb Company (\"Parent\"), and Gotham Merger Sub Inc., a direct wholly owned subsidiary of Parent (\"Merger Sub\"), pursuant to which Merger Sub completed a tender offer for shares of common stock of the Issuer (each, a \"Share\") and thereafter merged with and into the Issuer (the \"Merger\") effective as of November 17, 2020 (the \"Effective Time\"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $225.00 in cash (the \"Offer Price\") without interest and subject to applicable withholding taxes."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-20-031746","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1413822/000089924320031746/doc4.xml","form_type":"4"}},{"id":2972965,"issuer":{"id":145206,"kind":"organization","name":"MyoKardia, Inc.","symbol":"MYOK"},"owners":[{"id":36315,"kind":"person","name":"GIANAKAKOS ANASTASIOS","position":1,"cik":"0001413822","reported_name":"GIANAKAKOS ANASTASIOS","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2020-11-20T01:15:34.000Z","date":"2020-11-17","kind":"other","acquired":false,"shares":53087,"ownership":{"direct":false,"nature":"By Trust 1"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of October 3, 2020, by and among the Issuer, Bristol-Myers Squibb Company (\"Parent\"), and Gotham Merger Sub Inc., a direct wholly owned subsidiary of Parent (\"Merger Sub\"), pursuant to which Merger Sub completed a tender offer for shares of common stock of the Issuer (each, a \"Share\") and thereafter merged with and into the Issuer (the \"Merger\") effective as of November 17, 2020 (the \"Effective Time\"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $225.00 in cash (the \"Offer Price\") without interest and subject to applicable withholding taxes."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of October 3, 2020, by and among the Issuer, Bristol-Myers Squibb Company (\"Parent\"), and Gotham Merger Sub Inc., a direct wholly owned subsidiary of Parent (\"Merger Sub\"), pursuant to which Merger Sub completed a tender offer for shares of common stock of the Issuer (each, a \"Share\") and thereafter merged with and into the Issuer (the \"Merger\") effective as of November 17, 2020 (the \"Effective Time\"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $225.00 in cash (the \"Offer Price\") without interest and subject to applicable withholding taxes."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-20-031746","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1413822/000089924320031746/doc4.xml","form_type":"4"}},{"id":2972964,"issuer":{"id":145206,"kind":"organization","name":"MyoKardia, Inc.","symbol":"MYOK"},"owners":[{"id":36315,"kind":"person","name":"GIANAKAKOS ANASTASIOS","position":1,"cik":"0001413822","reported_name":"GIANAKAKOS ANASTASIOS","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2020-11-20T01:15:34.000Z","date":"2020-11-17","kind":"other","acquired":false,"shares":10000,"ownership":{"direct":false,"nature":"By reporting Person's Trust 6"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of October 3, 2020, by and among the Issuer, Bristol-Myers Squibb Company (\"Parent\"), and Gotham Merger Sub Inc., a direct wholly owned subsidiary of Parent (\"Merger Sub\"), pursuant to which Merger Sub completed a tender offer for shares of common stock of the Issuer (each, a \"Share\") and thereafter merged with and into the Issuer (the \"Merger\") effective as of November 17, 2020 (the \"Effective Time\"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $225.00 in cash (the \"Offer Price\") without interest and subject to applicable withholding taxes."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of October 3, 2020, by and among the Issuer, Bristol-Myers Squibb Company (\"Parent\"), and Gotham Merger Sub Inc., a direct wholly owned subsidiary of Parent (\"Merger Sub\"), pursuant to which Merger Sub completed a tender offer for shares of common stock of the Issuer (each, a \"Share\") and thereafter merged with and into the Issuer (the \"Merger\") effective as of November 17, 2020 (the \"Effective Time\"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $225.00 in cash (the \"Offer Price\") without interest and subject to applicable withholding taxes."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-20-031746","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1413822/000089924320031746/doc4.xml","form_type":"4"}},{"id":2972963,"issuer":{"id":145206,"kind":"organization","name":"MyoKardia, Inc.","symbol":"MYOK"},"owners":[{"id":36315,"kind":"person","name":"GIANAKAKOS ANASTASIOS","position":1,"cik":"0001413822","reported_name":"GIANAKAKOS ANASTASIOS","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2020-11-20T01:15:34.000Z","date":"2020-11-17","kind":"other","acquired":false,"shares":7000,"ownership":{"direct":false,"nature":"By Reporting Person's Trust 5"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of October 3, 2020, by and among the Issuer, Bristol-Myers Squibb Company (\"Parent\"), and Gotham Merger Sub Inc., a direct wholly owned subsidiary of Parent (\"Merger Sub\"), pursuant to which Merger Sub completed a tender offer for shares of common stock of the Issuer (each, a \"Share\") and thereafter merged with and into the Issuer (the \"Merger\") effective as of November 17, 2020 (the \"Effective Time\"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $225.00 in cash (the \"Offer Price\") without interest and subject to applicable withholding taxes."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of October 3, 2020, by and among the Issuer, Bristol-Myers Squibb Company (\"Parent\"), and Gotham Merger Sub Inc., a direct wholly owned subsidiary of Parent (\"Merger Sub\"), pursuant to which Merger Sub completed a tender offer for shares of common stock of the Issuer (each, a \"Share\") and thereafter merged with and into the Issuer (the \"Merger\") effective as of November 17, 2020 (the \"Effective Time\"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $225.00 in cash (the \"Offer Price\") without interest and subject to applicable withholding taxes."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-20-031746","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1413822/000089924320031746/doc4.xml","form_type":"4"}},{"id":2972962,"issuer":{"id":145206,"kind":"organization","name":"MyoKardia, Inc.","symbol":"MYOK"},"owners":[{"id":36315,"kind":"person","name":"GIANAKAKOS ANASTASIOS","position":1,"cik":"0001413822","reported_name":"GIANAKAKOS ANASTASIOS","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2020-11-20T01:15:34.000Z","date":"2020-11-17","kind":"other","acquired":false,"shares":300000,"ownership":{"direct":false,"nature":"By Reporting Person's Trust 4"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of October 3, 2020, by and among the Issuer, Bristol-Myers Squibb Company (\"Parent\"), and Gotham Merger Sub Inc., a direct wholly owned subsidiary of Parent (\"Merger Sub\"), pursuant to which Merger Sub completed a tender offer for shares of common stock of the Issuer (each, a \"Share\") and thereafter merged with and into the Issuer (the \"Merger\") effective as of November 17, 2020 (the \"Effective Time\"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $225.00 in cash (the \"Offer Price\") without interest and subject to applicable withholding taxes."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of October 3, 2020, by and among the Issuer, Bristol-Myers Squibb Company (\"Parent\"), and Gotham Merger Sub Inc., a direct wholly owned subsidiary of Parent (\"Merger Sub\"), pursuant to which Merger Sub completed a tender offer for shares of common stock of the Issuer (each, a \"Share\") and thereafter merged with and into the Issuer (the \"Merger\") effective as of November 17, 2020 (the \"Effective Time\"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $225.00 in cash (the \"Offer Price\") without interest and subject to applicable withholding taxes."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-20-031746","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1413822/000089924320031746/doc4.xml","form_type":"4"}},{"id":2972961,"issuer":{"id":145206,"kind":"organization","name":"MyoKardia, Inc.","symbol":"MYOK"},"owners":[{"id":36315,"kind":"person","name":"GIANAKAKOS ANASTASIOS","position":1,"cik":"0001413822","reported_name":"GIANAKAKOS ANASTASIOS","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2020-11-20T01:15:34.000Z","date":"2020-11-17","kind":"other","acquired":false,"shares":129407,"ownership":{"direct":false,"nature":"By Reporting Person's Trust 2"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of October 3, 2020, by and among the Issuer, Bristol-Myers Squibb Company (\"Parent\"), and Gotham Merger Sub Inc., a direct wholly owned subsidiary of Parent (\"Merger Sub\"), pursuant to which Merger Sub completed a tender offer for shares of common stock of the Issuer (each, a \"Share\") and thereafter merged with and into the Issuer (the \"Merger\") effective as of November 17, 2020 (the \"Effective Time\"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $225.00 in cash (the \"Offer Price\") without interest and subject to applicable withholding taxes."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of October 3, 2020, by and among the Issuer, Bristol-Myers Squibb Company (\"Parent\"), and Gotham Merger Sub Inc., a direct wholly owned subsidiary of Parent (\"Merger Sub\"), pursuant to which Merger Sub completed a tender offer for shares of common stock of the Issuer (each, a \"Share\") and thereafter merged with and into the Issuer (the \"Merger\") effective as of November 17, 2020 (the \"Effective Time\"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $225.00 in cash (the \"Offer Price\") without interest and subject to applicable withholding taxes."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-20-031746","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1413822/000089924320031746/doc4.xml","form_type":"4"}},{"id":2972960,"issuer":{"id":145206,"kind":"organization","name":"MyoKardia, Inc.","symbol":"MYOK"},"owners":[{"id":36315,"kind":"person","name":"GIANAKAKOS ANASTASIOS","position":1,"cik":"0001413822","reported_name":"GIANAKAKOS ANASTASIOS","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2020-11-20T01:15:34.000Z","date":"2020-11-17","kind":"other","acquired":false,"shares":141405,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of October 3, 2020, by and among the Issuer, Bristol-Myers Squibb Company (\"Parent\"), and Gotham Merger Sub Inc., a direct wholly owned subsidiary of Parent (\"Merger Sub\"), pursuant to which Merger Sub completed a tender offer for shares of common stock of the Issuer (each, a \"Share\") and thereafter merged with and into the Issuer (the \"Merger\") effective as of November 17, 2020 (the \"Effective Time\"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $225.00 in cash (the \"Offer Price\") without interest and subject to applicable withholding taxes."},{"field":"shares","element":"transactionShares","label":"F2","text":"A portion of this amount consists of unvested restricted stock units (\"RSUs\"). Pursuant to the terms of the Merger Agreement, each Issuer RSU that was outstanding immediately prior to the Effective Time, whether vested or unvested, was cancelled at the Effective Time and automatically converted into the right to receive for each Share underlying such RSU, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the Offer Price."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of October 3, 2020, by and among the Issuer, Bristol-Myers Squibb Company (\"Parent\"), and Gotham Merger Sub Inc., a direct wholly owned subsidiary of Parent (\"Merger Sub\"), pursuant to which Merger Sub completed a tender offer for shares of common stock of the Issuer (each, a \"Share\") and thereafter merged with and into the Issuer (the \"Merger\") effective as of November 17, 2020 (the \"Effective Time\"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $225.00 in cash (the \"Offer Price\") without interest and subject to applicable withholding taxes."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"A portion of this amount consists of unvested restricted stock units (\"RSUs\"). Pursuant to the terms of the Merger Agreement, each Issuer RSU that was outstanding immediately prior to the Effective Time, whether vested or unvested, was cancelled at the Effective Time and automatically converted into the right to receive for each Share underlying such RSU, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the Offer Price."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-20-031746","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1413822/000089924320031746/doc4.xml","form_type":"4"}},{"id":3087395,"issuer":{"id":145206,"kind":"organization","name":"MyoKardia, Inc.","symbol":"MYOK"},"owners":[{"id":36315,"kind":"person","name":"GIANAKAKOS ANASTASIOS","position":1,"cik":"0001413822","reported_name":"GIANAKAKOS ANASTASIOS","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2020-07-07T21:39:30.000Z","date":"2020-07-02","kind":"sale","acquired":false,"shares":3224,"price":94.2205,"value":303766.892,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 3, 2019."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents the weighted average price of the shares sold ranging from $94.01 to $94.75 per share."}],"balance_after":19122,"source":{"system":"sec-edgar","filing":"0000950123-20-006771","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1413822/000095012320006771/doc4.xml","form_type":"4"}},{"id":3087394,"issuer":{"id":145206,"kind":"organization","name":"MyoKardia, Inc.","symbol":"MYOK"},"owners":[{"id":36315,"kind":"person","name":"GIANAKAKOS ANASTASIOS","position":1,"cik":"0001413822","reported_name":"GIANAKAKOS ANASTASIOS","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2020-07-07T21:39:30.000Z","date":"2020-07-02","kind":"sale","acquired":false,"shares":1776,"price":93.5485,"value":166142.136,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 3, 2019."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average sale price of the shares sold ranging from $92.98 to $93.93 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2 and 3."}],"balance_after":22346,"source":{"system":"sec-edgar","filing":"0000950123-20-006771","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1413822/000095012320006771/doc4.xml","form_type":"4"}},{"id":3121966,"issuer":{"id":145206,"kind":"organization","name":"MyoKardia, Inc.","symbol":"MYOK"},"owners":[{"id":36315,"kind":"person","name":"GIANAKAKOS ANASTASIOS","position":1,"cik":"0001413822","reported_name":"GIANAKAKOS ANASTASIOS","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2020-06-04T20:24:49.000Z","date":"2020-06-02","kind":"sale","acquired":false,"shares":319,"price":104.6446,"value":33381.6274,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 3, 2019."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Represents the weighted average sale price of the shares sold ranging from $104.33 to $105.06 per share."}],"balance_after":24122,"source":{"system":"sec-edgar","filing":"0000899243-20-015250","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1413822/000089924320015250/doc4.xml","form_type":"4"}},{"id":3121965,"issuer":{"id":145206,"kind":"organization","name":"MyoKardia, Inc.","symbol":"MYOK"},"owners":[{"id":36315,"kind":"person","name":"GIANAKAKOS ANASTASIOS","position":1,"cik":"0001413822","reported_name":"GIANAKAKOS ANASTASIOS","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2020-06-04T20:24:49.000Z","date":"2020-06-02","kind":"sale","acquired":false,"shares":1885,"price":103.7716,"value":195609.466,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 3, 2019."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Represents the weighted average sale price of the shares sold ranging from $103.30 to $104.10 per share."}],"balance_after":24441,"source":{"system":"sec-edgar","filing":"0000899243-20-015250","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1413822/000089924320015250/doc4.xml","form_type":"4"}},{"id":3121964,"issuer":{"id":145206,"kind":"organization","name":"MyoKardia, Inc.","symbol":"MYOK"},"owners":[{"id":36315,"kind":"person","name":"GIANAKAKOS ANASTASIOS","position":1,"cik":"0001413822","reported_name":"GIANAKAKOS ANASTASIOS","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2020-06-04T20:24:49.000Z","date":"2020-06-02","kind":"sale","acquired":false,"shares":1396,"price":102.7804,"value":143481.4384,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 3, 2019."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents the weighted average sale price of the shares sold ranging from $102.30 to $103.04 per share."}],"balance_after":26326,"source":{"system":"sec-edgar","filing":"0000899243-20-015250","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1413822/000089924320015250/doc4.xml","form_type":"4"}},{"id":3121963,"issuer":{"id":145206,"kind":"organization","name":"MyoKardia, Inc.","symbol":"MYOK"},"owners":[{"id":36315,"kind":"person","name":"GIANAKAKOS ANASTASIOS","position":1,"cik":"0001413822","reported_name":"GIANAKAKOS ANASTASIOS","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2020-06-04T20:24:49.000Z","date":"2020-06-02","kind":"sale","acquired":false,"shares":800,"price":101.7225,"value":81378.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 3, 2019."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents the weighted average sale price of the shares sold ranging from $101.28 to $102.17 per share."}],"balance_after":27722,"source":{"system":"sec-edgar","filing":"0000899243-20-015250","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1413822/000089924320015250/doc4.xml","form_type":"4"}},{"id":3121962,"issuer":{"id":145206,"kind":"organization","name":"MyoKardia, Inc.","symbol":"MYOK"},"owners":[{"id":36315,"kind":"person","name":"GIANAKAKOS ANASTASIOS","position":1,"cik":"0001413822","reported_name":"GIANAKAKOS ANASTASIOS","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2020-06-04T20:24:49.000Z","date":"2020-06-02","kind":"sale","acquired":false,"shares":600,"price":100.595,"value":60357.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 3, 2019."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average sale price of the shares sold ranging from $100.27 to $101.22 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the ranges reported in footnotes 2, 3, 4, 5, and 6."}],"balance_after":28522,"source":{"system":"sec-edgar","filing":"0000899243-20-015250","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1413822/000089924320015250/doc4.xml","form_type":"4"}},{"id":3140679,"issuer":{"id":145206,"kind":"organization","name":"MyoKardia, Inc.","symbol":"MYOK"},"owners":[{"id":36315,"kind":"person","name":"GIANAKAKOS ANASTASIOS","position":1,"cik":"0001413822","reported_name":"GIANAKAKOS ANASTASIOS","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2020-05-20T20:55:59.000Z","date":"2020-05-18","kind":"sale","acquired":false,"shares":10000,"price":125,"value":1250000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person."}],"balance_after":29122,"source":{"system":"sec-edgar","filing":"0000899243-20-013695","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1413822/000089924320013695/doc4.xml","form_type":"4"}},{"id":3150675,"issuer":{"id":145206,"kind":"organization","name":"MyoKardia, Inc.","symbol":"MYOK"},"owners":[{"id":36315,"kind":"person","name":"GIANAKAKOS ANASTASIOS","position":1,"cik":"0001413822","reported_name":"GIANAKAKOS ANASTASIOS","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2020-05-13T21:15:31.000Z","date":"2020-05-11","kind":"sale","acquired":false,"shares":600,"price":103.33,"value":61998.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Represents the weighted average price of the shares sold ranging from $103.19 to $103.54 per share."}],"balance_after":39122,"source":{"system":"sec-edgar","filing":"0000899243-20-013004","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1413822/000089924320013004/doc4.xml","form_type":"4"}},{"id":3150674,"issuer":{"id":145206,"kind":"organization","name":"MyoKardia, Inc.","symbol":"MYOK"},"owners":[{"id":36315,"kind":"person","name":"GIANAKAKOS ANASTASIOS","position":1,"cik":"0001413822","reported_name":"GIANAKAKOS ANASTASIOS","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2020-05-13T21:15:31.000Z","date":"2020-05-11","kind":"sale","acquired":false,"shares":3519,"price":102.5635,"value":360920.9565,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Represents the weighted average price of the shares sold ranging from $102.11 to $103.09 per share."}],"balance_after":39722,"source":{"system":"sec-edgar","filing":"0000899243-20-013004","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1413822/000089924320013004/doc4.xml","form_type":"4"}},{"id":3150673,"issuer":{"id":145206,"kind":"organization","name":"MyoKardia, Inc.","symbol":"MYOK"},"owners":[{"id":36315,"kind":"person","name":"GIANAKAKOS ANASTASIOS","position":1,"cik":"0001413822","reported_name":"GIANAKAKOS ANASTASIOS","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2020-05-13T21:15:31.000Z","date":"2020-05-11","kind":"sale","acquired":false,"shares":18581,"price":101.9044,"value":1893485.6564,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Represents the weighted average price of the shares sold ranging from $101.07 to $102.05 per share."}],"balance_after":43241,"source":{"system":"sec-edgar","filing":"0000899243-20-013004","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1413822/000089924320013004/doc4.xml","form_type":"4"}},{"id":3150672,"issuer":{"id":145206,"kind":"organization","name":"MyoKardia, Inc.","symbol":"MYOK"},"owners":[{"id":36315,"kind":"person","name":"GIANAKAKOS ANASTASIOS","position":1,"cik":"0001413822","reported_name":"GIANAKAKOS ANASTASIOS","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2020-05-13T21:15:31.000Z","date":"2020-05-11","kind":"sale","acquired":false,"shares":1700,"price":100.5056,"value":170859.52,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents the weighted average price of the shares sold ranging from $100.01 to $100.94 per share."}],"balance_after":61822,"source":{"system":"sec-edgar","filing":"0000899243-20-013004","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1413822/000089924320013004/doc4.xml","form_type":"4"}},{"id":3150671,"issuer":{"id":145206,"kind":"organization","name":"MyoKardia, Inc.","symbol":"MYOK"},"owners":[{"id":36315,"kind":"person","name":"GIANAKAKOS ANASTASIOS","position":1,"cik":"0001413822","reported_name":"GIANAKAKOS ANASTASIOS","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2020-05-13T21:15:31.000Z","date":"2020-05-11","kind":"sale","acquired":false,"shares":600,"price":98.6883,"value":59212.98,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average sale price of the shares sold ranging from $98.50 to $99.46 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the ranges reported in this footnote and footnotes 4 through 7."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Excludes 10,000 shares previously owned directly which were contributed on May 6, 2020 to the MJA Legacy Trust, of which the Reporting Person's children are beneficiaries."}],"balance_after":63522,"source":{"system":"sec-edgar","filing":"0000899243-20-013004","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1413822/000089924320013004/doc4.xml","form_type":"4"}},{"id":3159339,"issuer":{"id":145206,"kind":"organization","name":"MyoKardia, Inc.","symbol":"MYOK"},"owners":[{"id":36315,"kind":"person","name":"GIANAKAKOS ANASTASIOS","position":1,"cik":"0001413822","reported_name":"GIANAKAKOS ANASTASIOS","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2020-05-06T23:07:36.000Z","date":"2020-05-04","kind":"sale","acquired":false,"shares":305,"price":60.152,"value":18346.36,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Represents the weighted average price of the shares sold ranging from $59.67 to $60.17 per share."}],"balance_after":74122,"source":{"system":"sec-edgar","filing":"0000899243-20-012163","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1413822/000089924320012163/doc4.xml","form_type":"4"}},{"id":3159338,"issuer":{"id":145206,"kind":"organization","name":"MyoKardia, Inc.","symbol":"MYOK"},"owners":[{"id":36315,"kind":"person","name":"GIANAKAKOS ANASTASIOS","position":1,"cik":"0001413822","reported_name":"GIANAKAKOS ANASTASIOS","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2020-05-06T23:07:36.000Z","date":"2020-05-04","kind":"sale","acquired":false,"shares":2909,"price":59.0979,"value":171915.7911,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Represents the weighted average price of the shares sold ranging from $58.60 to $59.45 per share."}],"balance_after":74427,"source":{"system":"sec-edgar","filing":"0000899243-20-012163","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1413822/000089924320012163/doc4.xml","form_type":"4"}},{"id":3159337,"issuer":{"id":145206,"kind":"organization","name":"MyoKardia, Inc.","symbol":"MYOK"},"owners":[{"id":36315,"kind":"person","name":"GIANAKAKOS ANASTASIOS","position":1,"cik":"0001413822","reported_name":"GIANAKAKOS ANASTASIOS","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2020-05-06T23:07:36.000Z","date":"2020-05-04","kind":"sale","acquired":false,"shares":400,"price":58.045,"value":23218.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents the weighted average price of the shares sold ranging from $57.48 to $58.40 per share."}],"balance_after":77336,"source":{"system":"sec-edgar","filing":"0000899243-20-012163","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1413822/000089924320012163/doc4.xml","form_type":"4"}},{"id":3159336,"issuer":{"id":145206,"kind":"organization","name":"MyoKardia, Inc.","symbol":"MYOK"},"owners":[{"id":36315,"kind":"person","name":"GIANAKAKOS ANASTASIOS","position":1,"cik":"0001413822","reported_name":"GIANAKAKOS ANASTASIOS","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2020-05-06T23:07:36.000Z","date":"2020-05-04","kind":"sale","acquired":false,"shares":1386,"price":56.9317,"value":78907.3362,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average sale price of the shares sold ranging from $56.46 to $57.35 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the ranges reported in footnotes 2, 4, 5 and 6."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 95,540 shares previously held by The TKG Trust dated November 2, 2006 which were contributed to the Reporting Person directly on May 1, 2020, and excludes (a) 300,000 shares previously owned directly which were contributed to The Tassos Gianakakos 2020 Annuity Trust on May 1, 2020 and (b) 6,000 shares previously owned directly which were contributed to The TKG 2020 Irrevocable Trust on May 1, 2020."}],"balance_after":77736,"source":{"system":"sec-edgar","filing":"0000899243-20-012163","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1413822/000089924320012163/doc4.xml","form_type":"4"}},{"id":3163527,"issuer":{"id":145206,"kind":"organization","name":"MyoKardia, Inc.","symbol":"MYOK"},"owners":[{"id":36315,"kind":"person","name":"GIANAKAKOS ANASTASIOS","position":1,"cik":"0001413822","reported_name":"GIANAKAKOS ANASTASIOS","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-05-04T21:34:42.000Z","date":"2020-04-30","kind":"exercise","acquired":false,"shares":11500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% of the shares subject to the option vested and became exercisable on June 4, 2016, and the remaining shares subject to this option vest and become exercisable in monthly installments through June 4, 2019, subject to the Reporting Person's continuous service to the Issuer through each vesting date."}],"balance_after":121626,"derivative":{"exercise_price":1.5068,"expiration_date":"2025-06-03","underlying":"Common Stock","underlying_shares":11500},"source":{"system":"sec-edgar","filing":"0000899243-20-011908","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1413822/000089924320011908/doc4.xml","form_type":"4"}},{"id":3163526,"issuer":{"id":145206,"kind":"organization","name":"MyoKardia, Inc.","symbol":"MYOK"},"owners":[{"id":36315,"kind":"person","name":"GIANAKAKOS ANASTASIOS","position":1,"cik":"0001413822","reported_name":"GIANAKAKOS ANASTASIOS","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2020-05-04T21:34:42.000Z","date":"2020-04-30","kind":"exercise","acquired":true,"shares":11500,"price":1.5068,"value":17328.2,"ownership":{"direct":true},"balance_after":289582,"source":{"system":"sec-edgar","filing":"0000899243-20-011908","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1413822/000089924320011908/doc4.xml","form_type":"4"}},{"id":3163525,"issuer":{"id":145206,"kind":"organization","name":"MyoKardia, Inc.","symbol":"MYOK"},"owners":[{"id":36315,"kind":"person","name":"GIANAKAKOS ANASTASIOS","position":1,"cik":"0001413822","reported_name":"GIANAKAKOS ANASTASIOS","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2020-05-04T21:34:42.000Z","date":"2020-04-30","kind":"grant","acquired":true,"shares":421,"price":50.4135,"value":21224.0835,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares acquired pursuant to the Issuer's Amended and Restated 2015 Employee Stock Purchase Plan in a transaction exempt under Rule 16b-3(c)."}],"balance_after":278082,"source":{"system":"sec-edgar","filing":"0000899243-20-011908","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1413822/000089924320011908/doc4.xml","form_type":"4"}},{"id":3173006,"issuer":{"id":145206,"kind":"organization","name":"MyoKardia, Inc.","symbol":"MYOK"},"owners":[{"id":36315,"kind":"person","name":"GIANAKAKOS ANASTASIOS","position":1,"cik":"0001413822","reported_name":"GIANAKAKOS ANASTASIOS","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2020-04-20T22:10:21.000Z","date":"2020-04-20","kind":"gift","acquired":false,"shares":122661,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Reporting Person's Trust 3"},"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-20-011019","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1413822/000089924320011019/doc4.xml","form_type":"4"}},{"id":3173005,"issuer":{"id":145206,"kind":"organization","name":"MyoKardia, Inc.","symbol":"MYOK"},"owners":[{"id":36315,"kind":"person","name":"GIANAKAKOS ANASTASIOS","position":1,"cik":"0001413822","reported_name":"GIANAKAKOS ANASTASIOS","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2020-04-20T22:10:21.000Z","date":"2020-04-17","kind":"gift","acquired":true,"shares":200865,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":277661,"source":{"system":"sec-edgar","filing":"0000899243-20-011019","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1413822/000089924320011019/doc4.xml","form_type":"4"}},{"id":3173004,"issuer":{"id":145206,"kind":"organization","name":"MyoKardia, Inc.","symbol":"MYOK"},"owners":[{"id":36315,"kind":"person","name":"GIANAKAKOS ANASTASIOS","position":1,"cik":"0001413822","reported_name":"GIANAKAKOS ANASTASIOS","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2020-04-20T22:10:21.000Z","date":"2020-04-17","kind":"gift","acquired":false,"shares":200865,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Reporting Person's Trust 3"},"balance_after":122661,"source":{"system":"sec-edgar","filing":"0000899243-20-011019","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1413822/000089924320011019/doc4.xml","form_type":"4"}},{"id":3173003,"issuer":{"id":145206,"kind":"organization","name":"MyoKardia, Inc.","symbol":"MYOK"},"owners":[{"id":36315,"kind":"person","name":"GIANAKAKOS ANASTASIOS","position":1,"cik":"0001413822","reported_name":"GIANAKAKOS ANASTASIOS","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2020-04-20T22:10:21.000Z","date":"2020-04-16","kind":"sale","acquired":false,"shares":1000,"price":55,"value":55000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person."}],"balance_after":76796,"source":{"system":"sec-edgar","filing":"0000899243-20-011019","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1413822/000089924320011019/doc4.xml","form_type":"4"}},{"id":3178489,"issuer":{"id":145206,"kind":"organization","name":"MyoKardia, Inc.","symbol":"MYOK"},"owners":[{"id":36315,"kind":"person","name":"GIANAKAKOS ANASTASIOS","position":1,"cik":"0001413822","reported_name":"GIANAKAKOS ANASTASIOS","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2020-04-10T22:27:24.000Z","date":"2020-04-08","kind":"sale","acquired":false,"shares":1500,"price":50,"value":75000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person."}],"balance_after":77796,"source":{"system":"sec-edgar","filing":"0000899243-20-010647","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1413822/000089924320010647/doc4.xml","form_type":"4"}},{"id":3181582,"issuer":{"id":145206,"kind":"organization","name":"MyoKardia, Inc.","symbol":"MYOK"},"owners":[{"id":36315,"kind":"person","name":"GIANAKAKOS ANASTASIOS","position":1,"cik":"0001413822","reported_name":"GIANAKAKOS ANASTASIOS","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2020-04-06T20:06:09.000Z","date":"2020-04-02","kind":"sale","acquired":false,"shares":600,"price":46.2267,"value":27736.02,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Represents the weighted average sale price of the shares sold ranging from $46.03 to $46.54 per share."}],"balance_after":79296,"source":{"system":"sec-edgar","filing":"0000899243-20-010312","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1413822/000089924320010312/doc4.xml","form_type":"4"}},{"id":3181581,"issuer":{"id":145206,"kind":"organization","name":"MyoKardia, Inc.","symbol":"MYOK"},"owners":[{"id":36315,"kind":"person","name":"GIANAKAKOS ANASTASIOS","position":1,"cik":"0001413822","reported_name":"GIANAKAKOS ANASTASIOS","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2020-04-06T20:06:09.000Z","date":"2020-04-02","kind":"sale","acquired":false,"shares":300,"price":45.35,"value":13605.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents the weighted average sale price of the shares sold ranging from $45.02 to $45.83 per share."}],"balance_after":79896,"source":{"system":"sec-edgar","filing":"0000899243-20-010312","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1413822/000089924320010312/doc4.xml","form_type":"4"}},{"id":3181580,"issuer":{"id":145206,"kind":"organization","name":"MyoKardia, Inc.","symbol":"MYOK"},"owners":[{"id":36315,"kind":"person","name":"GIANAKAKOS ANASTASIOS","position":1,"cik":"0001413822","reported_name":"GIANAKAKOS ANASTASIOS","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2020-04-06T20:06:09.000Z","date":"2020-04-02","kind":"sale","acquired":false,"shares":1000,"price":44.469,"value":44469.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents the weighted average sale price of the shares sold ranging from $43.99 to $44.97 per share."}],"balance_after":80196,"source":{"system":"sec-edgar","filing":"0000899243-20-010312","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1413822/000089924320010312/doc4.xml","form_type":"4"}},{"id":3181579,"issuer":{"id":145206,"kind":"organization","name":"MyoKardia, Inc.","symbol":"MYOK"},"owners":[{"id":36315,"kind":"person","name":"GIANAKAKOS ANASTASIOS","position":1,"cik":"0001413822","reported_name":"GIANAKAKOS ANASTASIOS","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2020-04-06T20:06:09.000Z","date":"2020-04-02","kind":"sale","acquired":false,"shares":600,"price":43.5117,"value":26107.02,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average sale price of the shares sold ranging from $42.91 to $43.89 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the ranges reported in footnotes 2 through 5."}],"balance_after":81196,"source":{"system":"sec-edgar","filing":"0000899243-20-010312","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1413822/000089924320010312/doc4.xml","form_type":"4"}},{"id":3227176,"issuer":{"id":145206,"kind":"organization","name":"MyoKardia, Inc.","symbol":"MYOK"},"owners":[{"id":36315,"kind":"person","name":"GIANAKAKOS ANASTASIOS","position":1,"cik":"0001413822","reported_name":"GIANAKAKOS ANASTASIOS","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2020-03-04T22:42:56.000Z","date":"2020-03-02","kind":"sale","acquired":false,"shares":22,"price":65.97,"value":1451.34,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person."}],"balance_after":81796,"source":{"system":"sec-edgar","filing":"0000899243-20-006984","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1413822/000089924320006984/doc4.xml","form_type":"4"}},{"id":3227175,"issuer":{"id":145206,"kind":"organization","name":"MyoKardia, Inc.","symbol":"MYOK"},"owners":[{"id":36315,"kind":"person","name":"GIANAKAKOS ANASTASIOS","position":1,"cik":"0001413822","reported_name":"GIANAKAKOS ANASTASIOS","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2020-03-04T22:42:56.000Z","date":"2020-03-02","kind":"sale","acquired":false,"shares":1800,"price":65.192,"value":117345.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents the weighted average sale price of the shares sold ranging from $64.89 to $65.82 per share."}],"balance_after":81818,"source":{"system":"sec-edgar","filing":"0000899243-20-006984","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1413822/000089924320006984/doc4.xml","form_type":"4"}},{"id":3227174,"issuer":{"id":145206,"kind":"organization","name":"MyoKardia, Inc.","symbol":"MYOK"},"owners":[{"id":36315,"kind":"person","name":"GIANAKAKOS ANASTASIOS","position":1,"cik":"0001413822","reported_name":"GIANAKAKOS ANASTASIOS","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2020-03-04T22:42:56.000Z","date":"2020-03-02","kind":"sale","acquired":false,"shares":2070,"price":64.3492,"value":133202.844,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents the weighted average sale price of the shares sold ranging from $63.80 to $64.74 per share."}],"balance_after":83618,"source":{"system":"sec-edgar","filing":"0000899243-20-006984","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1413822/000089924320006984/doc4.xml","form_type":"4"}},{"id":3227173,"issuer":{"id":145206,"kind":"organization","name":"MyoKardia, Inc.","symbol":"MYOK"},"owners":[{"id":36315,"kind":"person","name":"GIANAKAKOS ANASTASIOS","position":1,"cik":"0001413822","reported_name":"GIANAKAKOS ANASTASIOS","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2020-03-04T22:42:56.000Z","date":"2020-03-02","kind":"sale","acquired":false,"shares":1108,"price":63.3993,"value":70246.4244,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average sale price of the shares sold ranging from $62.77 to $63.76 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the ranges reported in footnotes 2 through 4."}],"balance_after":85688,"source":{"system":"sec-edgar","filing":"0000899243-20-006984","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1413822/000089924320006984/doc4.xml","form_type":"4"}},{"id":3227172,"issuer":{"id":145206,"kind":"organization","name":"MyoKardia, Inc.","symbol":"MYOK"},"owners":[{"id":36315,"kind":"person","name":"GIANAKAKOS ANASTASIOS","position":1,"cik":"0001413822","reported_name":"GIANAKAKOS ANASTASIOS","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-03-04T22:40:10.000Z","date":"2018-05-04","kind":"exercise","acquired":false,"shares":3000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person."},{"field":"shares","element":"transactionShares","label":"F2","text":"The Form 4 filed by the Reporting Person on May 7, 2018 incorrectly reported that the Reporting Person exercised stock options to purchase 2,981 shares of Common Stock and sold 3,000 shares of Common Stock in a same day sale. This Form 4/A hereby amends such entry to state that the Reporting Person exercised 3,000 shares of Common Stock underlying the options and sold 3,000 shares of Common Stock in a same day sale."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"25% of the shares subject to the option vested and became exercisable on June 4, 2016, and the remaining shares subject to this option vest and become exercisable in monthly installments through June 4, 2019, subject to the Reporting Person's continuous service to the Issuer."}],"balance_after":123235,"derivative":{"exercise_price":1.5068,"expiration_date":"2025-06-03","underlying":"Common Stock","underlying_shares":3000},"source":{"system":"sec-edgar","filing":"0000899243-20-006982","document":"doc4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1413822/000089924320006982/doc4a.xml","form_type":"4/A","original_submission_date":"2018-05-07"}},{"id":3227171,"issuer":{"id":145206,"kind":"organization","name":"MyoKardia, Inc.","symbol":"MYOK"},"owners":[{"id":36315,"kind":"person","name":"GIANAKAKOS ANASTASIOS","position":1,"cik":"0001413822","reported_name":"GIANAKAKOS ANASTASIOS","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2020-03-04T22:40:10.000Z","date":"2018-05-04","kind":"sale","acquired":false,"shares":1300,"price":47.95,"value":62335.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents the weighted average sale price of the shares sold ranging from $47.85 to $48.10 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":74968,"source":{"system":"sec-edgar","filing":"0000899243-20-006982","document":"doc4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1413822/000089924320006982/doc4a.xml","form_type":"4/A","original_submission_date":"2018-05-07"}},{"id":3227170,"issuer":{"id":145206,"kind":"organization","name":"MyoKardia, Inc.","symbol":"MYOK"},"owners":[{"id":36315,"kind":"person","name":"GIANAKAKOS ANASTASIOS","position":1,"cik":"0001413822","reported_name":"GIANAKAKOS ANASTASIOS","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2020-03-04T22:40:10.000Z","date":"2018-05-04","kind":"sale","acquired":false,"shares":1700,"price":47.2735,"value":80364.95,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents the weighted average sale price of the shares sold ranging from $46.80 to $47.70 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":76268,"source":{"system":"sec-edgar","filing":"0000899243-20-006982","document":"doc4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1413822/000089924320006982/doc4a.xml","form_type":"4/A","original_submission_date":"2018-05-07"}},{"id":3227169,"issuer":{"id":145206,"kind":"organization","name":"MyoKardia, Inc.","symbol":"MYOK"},"owners":[{"id":36315,"kind":"person","name":"GIANAKAKOS ANASTASIOS","position":1,"cik":"0001413822","reported_name":"GIANAKAKOS ANASTASIOS","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2020-03-04T22:40:10.000Z","date":"2018-05-04","kind":"exercise","acquired":true,"shares":3000,"price":1.5068,"value":4520.4,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person."},{"field":"shares","element":"transactionShares","label":"F2","text":"The Form 4 filed by the Reporting Person on May 7, 2018 incorrectly reported that the Reporting Person exercised stock options to purchase 2,981 shares of Common Stock and sold 3,000 shares of Common Stock in a same day sale. This Form 4/A hereby amends such entry to state that the Reporting Person exercised 3,000 shares of Common Stock underlying the options and sold 3,000 shares of Common Stock in a same day sale."}],"balance_after":77968,"source":{"system":"sec-edgar","filing":"0000899243-20-006982","document":"doc4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1413822/000089924320006982/doc4a.xml","form_type":"4/A","original_submission_date":"2018-05-07"}},{"id":3262770,"issuer":{"id":145206,"kind":"organization","name":"MyoKardia, Inc.","symbol":"MYOK"},"owners":[{"id":36315,"kind":"person","name":"GIANAKAKOS ANASTASIOS","position":1,"cik":"0001413822","reported_name":"GIANAKAKOS ANASTASIOS","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Restricted Stock Units","published_at":"2020-02-20T01:44:18.000Z","date":"2020-02-14","kind":"grant","acquired":true,"shares":46083,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock. The shares of Common Stock underlying the RSUs vest in equal annual installments over 4 years from January 1, 2020, so that all of the underlying shares shall be vested on January 1, 2024, subject to the Reporting Person's continued employment with the Issuer through each vesting date.  The RSUs are subject to accelerated vesting upon termination without cause after a change of control of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock. The shares of Common Stock underlying the RSUs vest in equal annual installments over 4 years from January 1, 2020, so that all of the underlying shares shall be vested on January 1, 2024, subject to the Reporting Person's continued employment with the Issuer through each vesting date.  The RSUs are subject to accelerated vesting upon termination without cause after a change of control of the Issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock. The shares of Common Stock underlying the RSUs vest in equal annual installments over 4 years from January 1, 2020, so that all of the underlying shares shall be vested on January 1, 2024, subject to the Reporting Person's continued employment with the Issuer through each vesting date.  The RSUs are subject to accelerated vesting upon termination without cause after a change of control of the Issuer."}],"balance_after":46083,"derivative":{"underlying":"Common Stock","underlying_shares":46083},"source":{"system":"sec-edgar","filing":"0000899243-20-005189","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1413822/000089924320005189/doc4.xml","form_type":"4"}},{"id":3262769,"issuer":{"id":145206,"kind":"organization","name":"MyoKardia, Inc.","symbol":"MYOK"},"owners":[{"id":36315,"kind":"person","name":"GIANAKAKOS ANASTASIOS","position":1,"cik":"0001413822","reported_name":"GIANAKAKOS ANASTASIOS","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-02-20T01:44:18.000Z","date":"2020-02-14","kind":"grant","acquired":true,"shares":142733,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the option vest in 48 equal monthly installments from January 1, 2020, so long as the Reporting Person continues to be an employee of the Issuer through each vesting date.  This option is subject to accelerated vesting upon termination without cause upon a change of control of the Issuer."}],"balance_after":142733,"derivative":{"exercise_price":70.4,"expiration_date":"2030-02-13","underlying":"Common Stock","underlying_shares":142733},"source":{"system":"sec-edgar","filing":"0000899243-20-005189","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1413822/000089924320005189/doc4.xml","form_type":"4"}},{"id":3288484,"issuer":{"id":145206,"kind":"organization","name":"MyoKardia, Inc.","symbol":"MYOK"},"owners":[{"id":36315,"kind":"person","name":"GIANAKAKOS ANASTASIOS","position":1,"cik":"0001413822","reported_name":"GIANAKAKOS ANASTASIOS","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2020-02-06T01:22:26.000Z","date":"2020-02-03","kind":"sale","acquired":false,"shares":1000,"price":69.744,"value":69744.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents the weighted average sale price of the shares sold ranging from $69.57 to $69.94 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":86777,"source":{"system":"sec-edgar","filing":"0000899243-20-003410","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1413822/000089924320003410/doc4.xml","form_type":"4"}},{"id":3288483,"issuer":{"id":145206,"kind":"organization","name":"MyoKardia, Inc.","symbol":"MYOK"},"owners":[{"id":36315,"kind":"person","name":"GIANAKAKOS ANASTASIOS","position":1,"cik":"0001413822","reported_name":"GIANAKAKOS ANASTASIOS","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2020-02-06T01:22:26.000Z","date":"2020-02-03","kind":"sale","acquired":false,"shares":4000,"price":69.2692,"value":277076.8,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average sale price of the shares sold ranging from $68.55 to $69.54 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":87777,"source":{"system":"sec-edgar","filing":"0000899243-20-003410","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1413822/000089924320003410/doc4.xml","form_type":"4"}},{"id":3311517,"issuer":{"id":145206,"kind":"organization","name":"MyoKardia, Inc.","symbol":"MYOK"},"owners":[{"id":36315,"kind":"person","name":"GIANAKAKOS ANASTASIOS","position":1,"cik":"0001413822","reported_name":"GIANAKAKOS ANASTASIOS","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2020-01-15T01:26:41.000Z","date":"2020-01-14","kind":"sale","acquired":false,"shares":5000,"price":75.3929,"value":376964.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average sale price of the shares sold ranging from $75.00 to $75.68 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":91777,"source":{"system":"sec-edgar","filing":"0000899243-20-001197","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1413822/000089924320001197/doc4.xml","form_type":"4"}},{"id":3316207,"issuer":{"id":145206,"kind":"organization","name":"MyoKardia, Inc.","symbol":"MYOK"},"owners":[{"id":36315,"kind":"person","name":"GIANAKAKOS ANASTASIOS","position":1,"cik":"0001413822","reported_name":"GIANAKAKOS ANASTASIOS","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2020-01-08T00:39:22.000Z","date":"2020-01-06","kind":"sale","acquired":false,"shares":12687,"price":68.4511,"value":868439.1057,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold to cover withholding taxes in connection with vesting of Restricted Stock Units reported on Form 4 filed by the Reporting Person on January 3, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average sale price of the shares sold ranging from $68.35 to $68.66 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":96777,"source":{"system":"sec-edgar","filing":"0000899243-20-000793","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1413822/000089924320000793/doc4.xml","form_type":"4"}},{"id":3322578,"issuer":{"id":145206,"kind":"organization","name":"MyoKardia, Inc.","symbol":"MYOK"},"owners":[{"id":36315,"kind":"person","name":"GIANAKAKOS ANASTASIOS","position":1,"cik":"0001413822","reported_name":"GIANAKAKOS ANASTASIOS","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Restricted Stock Units","published_at":"2020-01-04T01:18:43.000Z","date":"2020-01-01","kind":"exercise","acquired":false,"shares":20300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Restricted stock units convert into common stock on a one-for-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Each RSU represents a contingent right to receive one share of Issuer's Common Stock. The shares of Common Stock underlying the RSUs vest in equal annual installments over 4 years from January 1, 2019, so that all of the underlying shares shall be vested on January 1, 2023, subject to the Reporting Person's continued employment with the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause after a change of control of the Issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Each RSU represents a contingent right to receive one share of Issuer's Common Stock. The shares of Common Stock underlying the RSUs vest in equal annual installments over 4 years from January 1, 2019, so that all of the underlying shares shall be vested on January 1, 2023, subject to the Reporting Person's continued employment with the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause after a change of control of the Issuer."}],"balance_after":60900,"derivative":{"underlying":"Common Stock","underlying_shares":20300},"source":{"system":"sec-edgar","filing":"0000899243-20-000387","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1413822/000089924320000387/doc4.xml","form_type":"4"}},{"id":3322577,"issuer":{"id":145206,"kind":"organization","name":"MyoKardia, Inc.","symbol":"MYOK"},"owners":[{"id":36315,"kind":"person","name":"GIANAKAKOS ANASTASIOS","position":1,"cik":"0001413822","reported_name":"GIANAKAKOS ANASTASIOS","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Restricted Stock Units","published_at":"2020-01-04T01:18:43.000Z","date":"2020-01-01","kind":"exercise","acquired":false,"shares":7650,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Restricted stock units convert into common stock on a one-for-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of Issuer's Common Stock. The shares of Common Stock underlying the RSUs vest in equal annual installments over 4 years from January 1, 2018, so that all of the underlying shares shall be vested on January 1, 2022, subject to the Reporting Person's continued employment with the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause after a change of control of the Issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of Issuer's Common Stock. The shares of Common Stock underlying the RSUs vest in equal annual installments over 4 years from January 1, 2018, so that all of the underlying shares shall be vested on January 1, 2022, subject to the Reporting Person's continued employment with the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause after a change of control of the Issuer."}],"balance_after":15300,"derivative":{"underlying":"Common Stock","underlying_shares":7650},"source":{"system":"sec-edgar","filing":"0000899243-20-000387","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1413822/000089924320000387/doc4.xml","form_type":"4"}},{"id":3322576,"issuer":{"id":145206,"kind":"organization","name":"MyoKardia, Inc.","symbol":"MYOK"},"owners":[{"id":36315,"kind":"person","name":"GIANAKAKOS ANASTASIOS","position":1,"cik":"0001413822","reported_name":"GIANAKAKOS ANASTASIOS","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2020-01-04T01:18:43.000Z","date":"2020-01-03","kind":"sale","acquired":false,"shares":2084,"price":72.2728,"value":150616.5152,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Represents the weighted average sale price of the shares sold ranging from $72.03 to $72.73 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":109464,"source":{"system":"sec-edgar","filing":"0000899243-20-000387","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1413822/000089924320000387/doc4.xml","form_type":"4"}},{"id":3322575,"issuer":{"id":145206,"kind":"organization","name":"MyoKardia, Inc.","symbol":"MYOK"},"owners":[{"id":36315,"kind":"person","name":"GIANAKAKOS ANASTASIOS","position":1,"cik":"0001413822","reported_name":"GIANAKAKOS ANASTASIOS","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2020-01-04T01:18:43.000Z","date":"2020-01-03","kind":"sale","acquired":false,"shares":2616,"price":71.5927,"value":187286.5032,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Represents the weighted average sale price of the shares sold ranging from $70.99 to $71.98 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":111548,"source":{"system":"sec-edgar","filing":"0000899243-20-000387","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1413822/000089924320000387/doc4.xml","form_type":"4"}},{"id":3322574,"issuer":{"id":145206,"kind":"organization","name":"MyoKardia, Inc.","symbol":"MYOK"},"owners":[{"id":36315,"kind":"person","name":"GIANAKAKOS ANASTASIOS","position":1,"cik":"0001413822","reported_name":"GIANAKAKOS ANASTASIOS","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2020-01-04T01:18:43.000Z","date":"2020-01-03","kind":"sale","acquired":false,"shares":300,"price":70.35,"value":21105.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Represents the weighted average sale price of the shares sold ranging from $69.93 to $70.56 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":114164,"source":{"system":"sec-edgar","filing":"0000899243-20-000387","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1413822/000089924320000387/doc4.xml","form_type":"4"}},{"id":3322573,"issuer":{"id":145206,"kind":"organization","name":"MyoKardia, Inc.","symbol":"MYOK"},"owners":[{"id":36315,"kind":"person","name":"GIANAKAKOS ANASTASIOS","position":1,"cik":"0001413822","reported_name":"GIANAKAKOS ANASTASIOS","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2020-01-04T01:18:43.000Z","date":"2020-01-01","kind":"exercise","acquired":true,"shares":27950,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted stock units convert into common stock on a one-for-one basis."}],"balance_after":114464,"source":{"system":"sec-edgar","filing":"0000899243-20-000387","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1413822/000089924320000387/doc4.xml","form_type":"4"}},{"id":3352412,"issuer":{"id":145206,"kind":"organization","name":"MyoKardia, Inc.","symbol":"MYOK"},"owners":[{"id":36315,"kind":"person","name":"GIANAKAKOS ANASTASIOS","position":1,"cik":"0001413822","reported_name":"GIANAKAKOS ANASTASIOS","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2019-12-04T21:26:14.000Z","date":"2019-12-02","kind":"sale","acquired":false,"shares":4350,"price":65.1362,"value":283342.47,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents the weighted average sale price of the shares sold ranging from $64.66 to $65.65 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":86514,"source":{"system":"sec-edgar","filing":"0000899243-19-028482","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1413822/000089924319028482/doc4.xml","form_type":"4"}},{"id":3352411,"issuer":{"id":145206,"kind":"organization","name":"MyoKardia, Inc.","symbol":"MYOK"},"owners":[{"id":36315,"kind":"person","name":"GIANAKAKOS ANASTASIOS","position":1,"cik":"0001413822","reported_name":"GIANAKAKOS ANASTASIOS","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2019-12-04T21:26:14.000Z","date":"2019-12-02","kind":"sale","acquired":false,"shares":650,"price":64.2392,"value":41755.48,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average sale price of the shares sold ranging from $63.66 to $64.58 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":90864,"source":{"system":"sec-edgar","filing":"0000899243-19-028482","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1413822/000089924319028482/doc4.xml","form_type":"4"}},{"id":3378647,"issuer":{"id":145206,"kind":"organization","name":"MyoKardia, Inc.","symbol":"MYOK"},"owners":[{"id":36315,"kind":"person","name":"GIANAKAKOS ANASTASIOS","position":1,"cik":"0001413822","reported_name":"GIANAKAKOS ANASTASIOS","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2019-11-06T23:33:48.000Z","date":"2019-11-04","kind":"sale","acquired":false,"shares":5000,"price":59.0729,"value":295364.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents the weighted average sale price of the shares sold ranging from $58.71 to $59.47 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":91514,"source":{"system":"sec-edgar","filing":"0000899243-19-026831","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1413822/000089924319026831/doc4.xml","form_type":"4"}},{"id":3378646,"issuer":{"id":145206,"kind":"organization","name":"MyoKardia, Inc.","symbol":"MYOK"},"owners":[{"id":36315,"kind":"person","name":"GIANAKAKOS ANASTASIOS","position":1,"cik":"0001413822","reported_name":"GIANAKAKOS ANASTASIOS","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2019-11-06T23:33:48.000Z","date":"2019-10-31","kind":"grant","acquired":true,"shares":44,"price":40.069,"value":1763.036,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares acquired pursuant to the Issuer's 2013 Employee Stock Purchase Plan in a transaction exempt under Rule 16b-3(c)."}],"balance_after":96514,"source":{"system":"sec-edgar","filing":"0000899243-19-026831","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1413822/000089924319026831/doc4.xml","form_type":"4"}},{"id":3397364,"issuer":{"id":145206,"kind":"organization","name":"MyoKardia, Inc.","symbol":"MYOK"},"owners":[{"id":36315,"kind":"person","name":"GIANAKAKOS ANASTASIOS","position":1,"cik":"0001413822","reported_name":"GIANAKAKOS ANASTASIOS","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2019-10-04T21:27:46.000Z","date":"2019-10-03","kind":"sale","acquired":false,"shares":1000,"price":55,"value":55000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person."}],"balance_after":96470,"source":{"system":"sec-edgar","filing":"0000899243-19-025124","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1413822/000089924319025124/doc4.xml","form_type":"4"}},{"id":3397363,"issuer":{"id":145206,"kind":"organization","name":"MyoKardia, Inc.","symbol":"MYOK"},"owners":[{"id":36315,"kind":"person","name":"GIANAKAKOS ANASTASIOS","position":1,"cik":"0001413822","reported_name":"GIANAKAKOS ANASTASIOS","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2019-10-04T21:27:46.000Z","date":"2019-10-02","kind":"sale","acquired":false,"shares":758,"price":53.0973,"value":40247.7534,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person."}],"balance_after":97470,"source":{"system":"sec-edgar","filing":"0000899243-19-025124","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1413822/000089924319025124/doc4.xml","form_type":"4"}},{"id":3397362,"issuer":{"id":145206,"kind":"organization","name":"MyoKardia, Inc.","symbol":"MYOK"},"owners":[{"id":36315,"kind":"person","name":"GIANAKAKOS ANASTASIOS","position":1,"cik":"0001413822","reported_name":"GIANAKAKOS ANASTASIOS","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2019-10-04T21:27:46.000Z","date":"2019-10-02","kind":"sale","acquired":false,"shares":2542,"price":52.2947,"value":132933.1274,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person."}],"balance_after":98228,"source":{"system":"sec-edgar","filing":"0000899243-19-025124","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1413822/000089924319025124/doc4.xml","form_type":"4"}},{"id":3397361,"issuer":{"id":145206,"kind":"organization","name":"MyoKardia, Inc.","symbol":"MYOK"},"owners":[{"id":36315,"kind":"person","name":"GIANAKAKOS ANASTASIOS","position":1,"cik":"0001413822","reported_name":"GIANAKAKOS ANASTASIOS","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2019-10-04T21:27:46.000Z","date":"2019-10-02","kind":"sale","acquired":false,"shares":700,"price":51.3286,"value":35930.02,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person."}],"balance_after":100770,"source":{"system":"sec-edgar","filing":"0000899243-19-025124","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1413822/000089924319025124/doc4.xml","form_type":"4"}},{"id":3416171,"issuer":{"id":145206,"kind":"organization","name":"MyoKardia, Inc.","symbol":"MYOK"},"owners":[{"id":36315,"kind":"person","name":"GIANAKAKOS ANASTASIOS","position":1,"cik":"0001413822","reported_name":"GIANAKAKOS ANASTASIOS","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2019-09-12T20:16:32.000Z","date":"2019-09-11","kind":"sale","acquired":false,"shares":1000,"price":55,"value":55000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person."}],"balance_after":101470,"source":{"system":"sec-edgar","filing":"0000899243-19-023423","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1413822/000089924319023423/doc4.xml","form_type":"4"}},{"id":3421684,"issuer":{"id":145206,"kind":"organization","name":"MyoKardia, Inc.","symbol":"MYOK"},"owners":[{"id":36315,"kind":"person","name":"GIANAKAKOS ANASTASIOS","position":1,"cik":"0001413822","reported_name":"GIANAKAKOS ANASTASIOS","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2019-09-05T20:05:21.000Z","date":"2019-09-03","kind":"sale","acquired":false,"shares":1100,"price":54.0909,"value":59499.99,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents the weighted average sale price of the shares sold ranging from $53.56 to $54.36. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":102470,"source":{"system":"sec-edgar","filing":"0000899243-19-022824","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1413822/000089924319022824/doc4.xml","form_type":"4"}},{"id":3421683,"issuer":{"id":145206,"kind":"organization","name":"MyoKardia, Inc.","symbol":"MYOK"},"owners":[{"id":36315,"kind":"person","name":"GIANAKAKOS ANASTASIOS","position":1,"cik":"0001413822","reported_name":"GIANAKAKOS ANASTASIOS","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2019-09-05T20:05:21.000Z","date":"2019-09-03","kind":"sale","acquired":false,"shares":1000,"price":52.75,"value":52750.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents the weighted average sale price of the shares sold ranging from $52.11 to $53.05. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":103570,"source":{"system":"sec-edgar","filing":"0000899243-19-022824","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1413822/000089924319022824/doc4.xml","form_type":"4"}},{"id":3421682,"issuer":{"id":145206,"kind":"organization","name":"MyoKardia, Inc.","symbol":"MYOK"},"owners":[{"id":36315,"kind":"person","name":"GIANAKAKOS ANASTASIOS","position":1,"cik":"0001413822","reported_name":"GIANAKAKOS ANASTASIOS","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2019-09-05T20:05:21.000Z","date":"2019-09-03","kind":"sale","acquired":false,"shares":1900,"price":50.7025,"value":96334.75,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average sale price of the shares sold ranging from $50.44 to $51.26 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":104570,"source":{"system":"sec-edgar","filing":"0000899243-19-022824","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1413822/000089924319022824/doc4.xml","form_type":"4"}},{"id":3442297,"issuer":{"id":145206,"kind":"organization","name":"MyoKardia, Inc.","symbol":"MYOK"},"owners":[{"id":36315,"kind":"person","name":"GIANAKAKOS ANASTASIOS","position":1,"cik":"0001413822","reported_name":"GIANAKAKOS ANASTASIOS","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2019-08-09T21:11:11.000Z","date":"2019-08-08","kind":"sale","acquired":false,"shares":1000,"price":55.09,"value":55090.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person."}],"balance_after":106470,"source":{"system":"sec-edgar","filing":"0000899243-19-021467","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1413822/000089924319021467/doc4.xml","form_type":"4"}},{"id":3446886,"issuer":{"id":145206,"kind":"organization","name":"MyoKardia, Inc.","symbol":"MYOK"},"owners":[{"id":36315,"kind":"person","name":"GIANAKAKOS ANASTASIOS","position":1,"cik":"0001413822","reported_name":"GIANAKAKOS ANASTASIOS","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2019-08-05T20:05:52.000Z","date":"2019-08-02","kind":"sale","acquired":false,"shares":200,"price":53.8175,"value":10763.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents the weighted average sale price of the shares sold ranging from $53.77 to $53.86 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":107470,"source":{"system":"sec-edgar","filing":"0000899243-19-020987","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1413822/000089924319020987/doc4.xml","form_type":"4"}},{"id":3446885,"issuer":{"id":145206,"kind":"organization","name":"MyoKardia, Inc.","symbol":"MYOK"},"owners":[{"id":36315,"kind":"person","name":"GIANAKAKOS ANASTASIOS","position":1,"cik":"0001413822","reported_name":"GIANAKAKOS ANASTASIOS","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2019-08-05T20:05:52.000Z","date":"2019-08-02","kind":"sale","acquired":false,"shares":3800,"price":53.203,"value":202171.4,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average sale price of the shares sold ranging from $52.72 to $53.63 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":107670,"source":{"system":"sec-edgar","filing":"0000899243-19-020987","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1413822/000089924319020987/doc4.xml","form_type":"4"}},{"id":3457365,"issuer":{"id":145206,"kind":"organization","name":"MyoKardia, Inc.","symbol":"MYOK"},"owners":[{"id":36315,"kind":"person","name":"GIANAKAKOS ANASTASIOS","position":1,"cik":"0001413822","reported_name":"GIANAKAKOS ANASTASIOS","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2019-07-23T20:05:18.000Z","date":"2019-07-22","kind":"sale","acquired":false,"shares":1000,"price":55,"value":55000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person."}],"balance_after":111470,"source":{"system":"sec-edgar","filing":"0000899243-19-020095","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1413822/000089924319020095/doc4.xml","form_type":"4"}},{"id":3465819,"issuer":{"id":145206,"kind":"organization","name":"MyoKardia, Inc.","symbol":"MYOK"},"owners":[{"id":36315,"kind":"person","name":"GIANAKAKOS ANASTASIOS","position":1,"cik":"0001413822","reported_name":"GIANAKAKOS ANASTASIOS","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2019-07-08T21:35:08.000Z","date":"2019-07-05","kind":"sale","acquired":false,"shares":2450,"price":50.1028,"value":122751.86,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents the weighted average sale price of the shares sold ranging from $49.82 to $50.49 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":112470,"source":{"system":"sec-edgar","filing":"0000899243-19-019317","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1413822/000089924319019317/doc4.xml","form_type":"4"}},{"id":3465818,"issuer":{"id":145206,"kind":"organization","name":"MyoKardia, Inc.","symbol":"MYOK"},"owners":[{"id":36315,"kind":"person","name":"GIANAKAKOS ANASTASIOS","position":1,"cik":"0001413822","reported_name":"GIANAKAKOS ANASTASIOS","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2019-07-08T21:35:08.000Z","date":"2019-07-05","kind":"sale","acquired":false,"shares":1550,"price":49.1298,"value":76151.19,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents the weighted average sale price of the shares sold ranging from $48.68 to $49.59 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":114920,"source":{"system":"sec-edgar","filing":"0000899243-19-019317","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1413822/000089924319019317/doc4.xml","form_type":"4"}},{"id":3465817,"issuer":{"id":145206,"kind":"organization","name":"MyoKardia, Inc.","symbol":"MYOK"},"owners":[{"id":36315,"kind":"person","name":"GIANAKAKOS ANASTASIOS","position":1,"cik":"0001413822","reported_name":"GIANAKAKOS ANASTASIOS","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2019-07-08T21:35:08.000Z","date":"2019-06-18","kind":"gift","acquired":false,"shares":39000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Reporting Person's Trust 2"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transfer of shares to Reporting Person from Reporting Person's Trust 2."}],"balance_after":49473,"source":{"system":"sec-edgar","filing":"0000899243-19-019317","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1413822/000089924319019317/doc4.xml","form_type":"4"}},{"id":3465816,"issuer":{"id":145206,"kind":"organization","name":"MyoKardia, Inc.","symbol":"MYOK"},"owners":[{"id":36315,"kind":"person","name":"GIANAKAKOS ANASTASIOS","position":1,"cik":"0001413822","reported_name":"GIANAKAKOS ANASTASIOS","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2019-07-08T21:35:08.000Z","date":"2019-06-18","kind":"gift","acquired":true,"shares":39000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transfer of shares to Reporting Person from Reporting Person's Trust 2."}],"balance_after":116470,"source":{"system":"sec-edgar","filing":"0000899243-19-019317","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1413822/000089924319019317/doc4.xml","form_type":"4"}},{"id":3504510,"issuer":{"id":145206,"kind":"organization","name":"MyoKardia, Inc.","symbol":"MYOK"},"owners":[{"id":36315,"kind":"person","name":"GIANAKAKOS ANASTASIOS","position":1,"cik":"0001413822","reported_name":"GIANAKAKOS ANASTASIOS","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2019-06-03T21:48:21.000Z","date":"2019-04-30","kind":"grant","acquired":true,"shares":503,"price":40.783,"value":20513.849,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares acquired pursuant to the Issuer's 2013 Employee Stock Purchase Plan in a transaction exempt under Rule 16b-3(c)."}],"balance_after":77470,"source":{"system":"sec-edgar","filing":"0000899243-19-015395","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1413822/000089924319015395/doc4.xml","form_type":"4"}},{"id":3662868,"issuer":{"id":145206,"kind":"organization","name":"MyoKardia, Inc.","symbol":"MYOK"},"owners":[{"id":36315,"kind":"person","name":"GIANAKAKOS ANASTASIOS","position":1,"cik":"0001413822","reported_name":"GIANAKAKOS ANASTASIOS","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Restricted Stock Units","published_at":"2019-02-12T21:23:48.000Z","date":"2019-02-08","kind":"grant","acquired":true,"shares":81200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of Issuer's Common Stock. The shares of Common Stock underlying the RSUs vest in equal annual installments over 4 years from January 1, 2019, so that all of the underlying shares shall be vested on January 1, 2023, subject to the Reporting Person's continued employment with the Issuer through each vesting date.  The RSUs are subject to accelerated vesting upon termination without cause after a change of control of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of Issuer's Common Stock. The shares of Common Stock underlying the RSUs vest in equal annual installments over 4 years from January 1, 2019, so that all of the underlying shares shall be vested on January 1, 2023, subject to the Reporting Person's continued employment with the Issuer through each vesting date.  The RSUs are subject to accelerated vesting upon termination without cause after a change of control of the Issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of Issuer's Common Stock. The shares of Common Stock underlying the RSUs vest in equal annual installments over 4 years from January 1, 2019, so that all of the underlying shares shall be vested on January 1, 2023, subject to the Reporting Person's continued employment with the Issuer through each vesting date.  The RSUs are subject to accelerated vesting upon termination without cause after a change of control of the Issuer."}],"balance_after":81200,"derivative":{"underlying":"Common Stock","underlying_shares":81200},"source":{"system":"sec-edgar","filing":"0000899243-19-003283","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1413822/000089924319003283/doc4.xml","form_type":"4"}},{"id":3662867,"issuer":{"id":145206,"kind":"organization","name":"MyoKardia, Inc.","symbol":"MYOK"},"owners":[{"id":36315,"kind":"person","name":"GIANAKAKOS ANASTASIOS","position":1,"cik":"0001413822","reported_name":"GIANAKAKOS ANASTASIOS","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2019-02-12T21:23:48.000Z","date":"2019-02-08","kind":"grant","acquired":true,"shares":236500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the option vest in 48 equal monthly installments from January 1, 2019, so long as the Reporting Person continues to be an employee of the Issuer through each vesting date.  This option is subject to accelerated vesting upon termination without cause upon a change of control of the Issuer."}],"balance_after":236500,"derivative":{"exercise_price":40.11,"expiration_date":"2029-02-07","underlying":"Common Stock","underlying_shares":236500},"source":{"system":"sec-edgar","filing":"0000899243-19-003283","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1413822/000089924319003283/doc4.xml","form_type":"4"}},{"id":3697217,"issuer":{"id":145206,"kind":"organization","name":"MyoKardia, Inc.","symbol":"MYOK"},"owners":[{"id":36315,"kind":"person","name":"GIANAKAKOS ANASTASIOS","position":1,"cik":"0001413822","reported_name":"GIANAKAKOS ANASTASIOS","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2019-01-12T01:18:34.000Z","date":"2019-01-07","kind":"sale","acquired":false,"shares":2770,"price":44.1146,"value":122197.442,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold to cover withholding taxes in connection with vesting of Restricted Stock Units reported on Form 4 filed by the Reporting Person on January 3, 2019."}],"balance_after":76967,"source":{"system":"sec-edgar","filing":"0000899243-19-001073","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1413822/000089924319001073/doc4.xml","form_type":"4"}}],"next_cursor":"2019-01-12T01:18:34.000000Z,3697217"}